Cell therapy · developed by Nanjing Legend Biotech
LUCAR-G79 is a T-cell therapy studied in relapsed or refractory autoimmune diseases.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07049081 | Phase 1 | Relapsed/Refractory Autoimmune Diseases | Terminated | LEGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Relapsed/Refractory Autoimmune Diseases
Updated Oct 18, 2026. Something wrong or missing? Report it on the LEGN page.
See LEGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LEGN catalysts and pipeline →